Component

Human CPAP use

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. CPAP use was not adversely affected during the twelve-week modafinil OSA trial; longer-term adherence mediation remains untested here.

    Modafinil → Human CPAP use Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary indexed abstract checked; full methods and figures not comprehensively reviewed.
    experimental_contrast
    {"intervention": "Adjunct modafinil", "comparator": "Placebo adjunct", "endpoint": "CPAP use was not adversely affected during the twelve-week modafinil OSA trial; longer-term adherence mediation remains untested here.", "effect_direction": "no_detected_change", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    CPAP-treated OSA, human randomized trial.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
    plain_language
    CPAP use was not adversely affected during the twelve-week modafinil OSA trial; longer-term adherence mediation remains untested here.
    primary_references
    Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. | 2005 | DOI 10.1093/sleep/28.4.464 | PMID 16171291 | https://pubmed.ncbi.nlm.nih.gov/16171291/
    source_locator
    Reviewed reference lines 170-170; exact primary location described in quoted passage where extracted.

    Modafinil: detailed mechanisms of action (reviewed 3 October 2026) · lines 170–170

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · CPAP-treated OSA, human randomized trial. · Recorded from source · Recorded from source

    For OSA, a 12-week randomized trial showed improved residual sleepiness and functioning in CPAP-treated patients and no adverse effect on CPAP use during that study. This is genuine symptomatic benefit; it does not show correction of airway obstruction or prevention of long-term vascular events. [OSA trial](https://pubmed.ncbi.nlm.nih.gov/16171291/)
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.